Optimizing Antiplatelet Therapy in the ACS Patient: Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel

Faculty

Elliott M. Antman, MD, FACC
Professor of Medicine
Harvard University School of Medicine
Senior Investigator, TIMI Study Group
Director, Samuel A. Levine Cardiac Unit
Brigham and Women's Hospital

Needs Statement

This presentation focuses on the results of the TRITON-TIMI 38 trial, which examines the use of the investigational thienopyridine prasugrel compared to clopidogrel in patients with ACS who were undergoing primary PCI. Highlighted data from the trial is presented, including several in-depth analyses investigating sub-populations as it relates to ischemic endpoints as well as bleeding events.

Target Audience

This activity is intended for interventional cardiologists, general cardiologists, internists and other healthcare professionals involved in the management of patients experiencing an acute coronary syndrome.

Objectives

1. Describe the primary results of the TRITON-TIMI 38 results with prasugrel;
2. Identify pertinent secondary endpoints from the TRITON-TIMI 38 results and;
3. Examine patient sub-populations which demonstrated increased risk of bleeding events.

Accreditation

Medicine
The University of Kentucky College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Each physician should claim only those hours of credit actually spent in the educational activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Faculty Disclosure

Dr. Antman has received research support from Eli Lilly and Co. and Daiichi-Sankyo, Inc.

Activity Sponsorship